AstraZeneca (AZN) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AZN Analyst Ratings

Strong Buy

11 Buy

1 Hold

1 Sell

Based on 13 analysts giving stock ratings to

AstraZeneca

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

kr1,768.76

▲(10.13% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is kr1,768.76 with a high forecast of kr2,246.68 and a low forecast of kr1,310.56. The average price target represents a 10.13% change from the last price of kr1,606.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1309":"kr1,309","1778":"kr1,778","2247":"kr2,247","1543.5":"kr1,543.5","2012.5":"kr2,012.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2246.67504,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr2.25K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1768.75733288,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr1.77K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1310.56044,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr1.31K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1309,1543.5,1778,2012.5,2247],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1554,1607.2826953846154,1660.5653907692308,1713.8480861538462,1767.1307815384616,1820.413476923077,1873.6961723076924,1926.9788676923076,1980.2615630769233,2033.5442584615384,2086.826953846154,2140.1096492307693,2193.392344615385,{"y":2246.67504,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1554,1570.519794836923,1587.0395896738462,1603.5593845107692,1620.0791793476924,1636.5989741846154,1653.1187690215384,1669.6385638584616,1686.1583586953845,1702.6781535323075,1719.1979483692307,1735.7177432061537,1752.237538043077,{"y":1768.75733288,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1554,1535.27388,1516.54776,1497.82164,1479.09552,1460.3694,1441.64328,1422.91716,1404.19104,1385.46492,1366.7388,1348.01268,1329.28656,{"y":1310.56044,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1493.569,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1441.206,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1415.758,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1532.719,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1610.833,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1459.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1388.375,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1359.575,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1352.623,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1416.679,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1508,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1568,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1554,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr2,247

Average Price Targetkr1,769

Lowest Price Targetkr1,311

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Veda Pharmyne

TR | OpenAI - 4o

kr1,746.29→kr1,752.91

Buy

9.15%

Upside

Reiterated

11/07/25

AI Generated ArticleAI Generated Article

Emmanuel Papadakis

Deutsche Bank

kr1,310.62

Sell

-18.39%

Downside

Reiterated

11/07/25

Deutsche Bank Sticks to Its Sell Rating for AstraZeneca (AZN)

Matthew Weston

UBS

kr1,772.45

Buy

10.36%

Upside

Reiterated

11/07/25

UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

kr1,892.65→kr1,935.22

Buy

20.50%

Upside

Reiterated

11/07/25

Sachin Jain

Bank of America Securities

kr1,809.82

Buy

12.69%

Upside

Reiterated

11/06/25

AstraZeneca: Strong Financial Performance and Promising Pipeline Support Buy Rating

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

kr1,809.82

Buy

12.69%

Upside

Reiterated

11/06/25

Shore Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)

Michael Leuchten

Jefferies

kr1,360.49→kr1,872.23

Buy

16.58%

Upside

Upgraded

10/26/25

Positive Report for AstraZeneca (AZN) from Jefferies

Richard Vosser

J.P. Morgan

kr1,747.49

Buy

8.81%

Upside

Reiterated

10/24/25

AstraZeneca (AZN) Receives a Buy from J.P. Morgan

Luisa Hector

Berenberg Bank

kr1,772.45→kr1,809.9

Buy

12.70%

Upside

Reiterated

10/22/25

AstraZeneca (AZN) Gets a Buy from Berenberg Bank

David Evans

Kepler Capital

kr1,410.41

Hold

-12.18%

Downside

Reiterated

10/22/25

Kepler Capital Sticks to Its Hold Rating for AstraZeneca (AZN)

Shirley Chen

Barclays

kr1,747.49

Buy

8.81%

Upside

Reiterated

10/21/25

Sarita Kapila

Morgan Stanley

kr1,710.04

Buy

6.48%

Upside

Reiterated

10/17/25

AstraZeneca (AZN) Gets a Buy from Morgan Stanley

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

kr1,685.01→kr1,809.82

Buy

12.69%

Upside

Reiterated

10/07/25

Shore Capital Sticks to Its Buy Rating for AstraZeneca (AZN)

Justin Smith

Bernstein

kr2,246.77

Buy

39.90%

Upside

Reiterated

10/07/25

Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)

Steve Scala

TD Cowen

kr1,854.76

Buy

15.49%

Upside

Reiterated

08/29/25

AstraZeneca's Promising Outlook: Buy Rating Backed by Baxdrostat's Potential and Strategic Positioning

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Veda Pharmyne

TR | OpenAI - 4o

kr1,746.29→kr1,752.91

Buy

9.15%

Upside

Reiterated

11/07/25

AI Generated ArticleAI Generated Article

Emmanuel Papadakis

Deutsche Bank

kr1,310.62

Sell

-18.39%

Downside

Reiterated

11/07/25

Deutsche Bank Sticks to Its Sell Rating for AstraZeneca (AZN)

Matthew Weston

UBS

kr1,772.45

Buy

10.36%

Upside

Reiterated

11/07/25

UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

kr1,892.65→kr1,935.22

Buy

20.50%

Upside

Reiterated

11/07/25

Sachin Jain

Bank of America Securities

kr1,809.82

Buy

12.69%

Upside

Reiterated

11/06/25

AstraZeneca: Strong Financial Performance and Promising Pipeline Support Buy Rating

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

kr1,809.82

Buy

12.69%

Upside

Reiterated

11/06/25

Shore Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)

Michael Leuchten

Jefferies

kr1,360.49→kr1,872.23

Buy

16.58%

Upside

Upgraded

10/26/25

Positive Report for AstraZeneca (AZN) from Jefferies

Richard Vosser

J.P. Morgan

kr1,747.49

Buy

8.81%

Upside

Reiterated

10/24/25

AstraZeneca (AZN) Receives a Buy from J.P. Morgan

Luisa Hector

Berenberg Bank

kr1,772.45→kr1,809.9

Buy

12.70%

Upside

Reiterated

10/22/25

AstraZeneca (AZN) Gets a Buy from Berenberg Bank

David Evans

Kepler Capital

kr1,410.41

Hold

-12.18%

Downside

Reiterated

10/22/25

Kepler Capital Sticks to Its Hold Rating for AstraZeneca (AZN)

Shirley Chen

Barclays

kr1,747.49

Buy

8.81%

Upside

Reiterated

10/21/25

Sarita Kapila

Morgan Stanley

kr1,710.04

Buy

6.48%

Upside

Reiterated

10/17/25

AstraZeneca (AZN) Gets a Buy from Morgan Stanley

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

kr1,685.01→kr1,809.82

Buy

12.69%

Upside

Reiterated

10/07/25

Shore Capital Sticks to Its Buy Rating for AstraZeneca (AZN)

Justin Smith

Bernstein

kr2,246.77

Buy

39.90%

Upside

Reiterated

10/07/25

Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)

Steve Scala

TD Cowen

kr1,854.76

Buy

15.49%

Upside

Reiterated

08/29/25

AstraZeneca's Promising Outlook: Buy Rating Backed by Baxdrostat's Potential and Strategic Positioning

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

1 Month

xxx

Success Rate

21/33 ratings generated profit

Average Return

+2.28%

upgraded a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +2.28% per trade.

3 Months

xxx

Success Rate

35/55 ratings generated profit

Average Return

+5.48%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +5.48% per trade.

1 Year

Matthew WestonUBS

Success Rate

32/35 ratings generated profit

Average Return

+15.32%

reiterated a buy rating 2 days ago

Copying Matthew Weston's trades and holding each position for 1 Year would result in 91.43% of your transactions generating a profit, with an average return of +15.32% per trade.

2 Years

xxx

Success Rate

32/35 ratings generated profit

Average Return

+22.77%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 91.43% of your transactions generating a profit, with an average return of +22.77% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AZN has received 28 Buy Ratings, 5 Hold Ratings, and 2 Sell Ratings. AZN average Analyst price target in the past 3 months is 1,768.76.

Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is kr20.37 with a range of kr18.20 to kr21.64. The previous quarter’s EPS was kr22.79. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year AZN has Preformed in-line its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is kr147.60B with a range of kr145.02B to kr151.18B. The previous quarter’s sales results were kr141.64B. AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year AZN has Preformed in-line its overall industry.

AZN Stock Forecast FAQ

What is SE:AZN’s average 12-month price target, according to analysts?

Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 1,768.76.

What is SE:AZN’s upside potential, based on the analysts’ average price target?

AstraZeneca PLC has 10.13% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AstraZeneca PLC a Buy, Sell or Hold?

AstraZeneca PLC has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 1 sell ratings.

What is AstraZeneca PLC’s share price target?

The average share price target for AstraZeneca PLC is 1,768.76. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr2,246.68 ,and the lowest forecast is kr1,310.56. The average share price target represents 10.13% Increase from the current price of kr1,606.

What do analysts say about AstraZeneca PLC?

AstraZeneca PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of AstraZeneca PLC?

To buy shares of SE:AZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

AstraZeneca (AZN) Stock Forecast & Price Target

AZN Analyst Ratings

AZN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AstraZeneca

AZN Analyst Recommendation Trends

AZN Financial Forecast

AZN Earnings Forecast

AZN Sales Forecast

AZN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts